Key Insights:
- Massive Molecule Access: Over 10¹⁶ virtual compounds and 8M+ in-stock molecules are now accessible through the combined Receptor.AI and Reaxense ecosystem.
- AI Meets Real-World Chemistry: Seamless integration accelerates synthesis and validation of AI-generated candidates, bridging a long-standing drug discovery bottleneck.
- Strategic Leap in Full-Stack Innovation: The move solidifies Receptor.AI’s position as a leader in end-to-end AI-driven drug design—from virtual screening to lab-ready compounds.
Advanced Chemistry at Scale
Receptor.AI has incorporated the REAXENSE™ platform, developed by Canada-based Reaxense Inc., into its ecosystem, enhancing access to four advanced chemical libraries. These include ChemoVista™ with over 8 million in-stock molecules, and VirtuSynthium™, a synthesis-ready space of 10¹⁶ virtual compounds. Together, they allow AI-designed drug candidates to be rapidly synthesized and tested—improving both turnaround time and hit quality.
Peptides and Macrocycles Reinvented
The integration brings new capabilities via OmniPeptide Nexus™ and MacroCyclePro™, enabling real-time 3D peptide modeling, ADMET profiling, and macrocycle design. These tools expand Receptor.AI’s reach to previously “undruggable” targets such as protein–protein interactions and beyond Rule of 5 (bRo5) space.
From Digital Prediction to Physical Validation
Receptor.AI’s AI models are now fully linked with Reaxense’s synthesis and reagent knowledge base, ensuring candidates are not only theoretically effective but chemically and commercially feasible. The joint system has shown marked improvements in early pilot runs, closing the loop between computational design and experimental delivery.
Paving the Path to Fully Autonomous Discovery
With this move, Receptor.AI deepens its ambition to deliver true full-stack drug discovery—from generative AI design to compound synthesis—at scale. “This is a foundational milestone,” said CEO Alan Nafiiev, “to democratize precision drug development across global biotech pipelines.”
About Receptor.AI
Receptor.AI is a Boston-based TechBio company specializing in generative AI for drug discovery. Its end-to-end platform integrates de novo molecular design, peptide engineering, and induced proximity targeting to accelerate the development of novel therapeutics. With a focus on challenging and previously “undruggable” targets, Receptor.AI partners with pharma, biotech, and academia to deliver AI-optimized, synthesis-ready drug candidates with unprecedented speed, precision, and scalability.
About Reaxense Inc.
Reaxense Inc. is a Canadian life sciences company based in Ontario, focused on advancing drug discovery through AI-powered chemical synthesis and custom molecular design. Its REAXENSE™ platform integrates vast curated and virtual chemical libraries with intelligent synthesis technologies, enabling researchers to access drug-like molecules across over 8,500 biological targets. Reaxense supports pharmaceutical, biotech, and academic partners with rapid, data-driven solutions tailored for hit discovery, lead optimization, and beyond.
By
